Streetbeat News

Revenues

UTI

Universal Technical Institute (UTI) has updated its fiscal year 2024 earnings per share (EPS) guidance to a range of $0.68-$0.73, up from the previous range of $0.67-$0.72. Additionally, UTI raised its revenue guidance for FY24 from $710 million-$720 million to $720 million-$730 million, surpassing the estimated $715.79 million.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:35 pm

XPER

Xperi has reaffirmed its fiscal year 2024 revenue outlook, projecting revenues to be in the range of $500 million to $530 million, with an estimated midpoint of $515.174 million.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:34 pm

PBPB

Potbelly Corporation has reaffirmed its long-term growth projections, expecting Q2 same store sales growth to range from 0.0% to 2.0%. For 2024, the company anticipates same store sales percentage growth to be in the low-single digits.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:32 pm

PSNL

Personalis, Inc. projects its Q2 revenue to be between $19.5M and $20.5M, surpassing the estimated $18.41M. This forecast suggests a positive outlook for the company's financial performance.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:32 pm

COMP

Compass projects its Q2 2024 revenue to be between $1.6 billion and $1.7 billion, compared to the estimated $1.626 billion.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:31 pm

BLND

Blend Labs provided guidance for Q2, expecting Blend Platform Segment Revenue to be between $27M-$30M and Title Revenue between $10.5M-$11.5M. The guidance is based on an estimated 935,000 - 1,025,000 U.S. aggregate industry mortgage originations for 2Q24. Additionally, Blend anticipates a Non-GAAP Net Operating Loss of ($10.5) – ($7.5) million.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:29 pm

APLM

Apollomics Inc. (NASDAQ:APLM) announced a private placement financing deal expected to generate approximately $6 million in gross proceeds. The company will sell around 19.2 million Class A ordinary shares at $0.30 each to both new and existing investors. The financing is set to close on May 8, 2024, and the funds will be used to support Apollomics' oncology drug development programs and for general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:28 pm

SEER

Seer, Inc. projects its FY24 revenue to be between $16M and $18M, which falls below the analyst estimate of $18.9M.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:27 pm

COOK

Traeger, Inc. projects its FY24 revenue to be between $580M-$605M, compared to the estimated $591.845M by analysts.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:27 pm

SUPN

Supernus Pharmaceuticals has reaffirmed its fiscal year 2024 revenue forecast to be in the range of $580 million to $620 million, which is in line with the analyst estimate of $601.461 million.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 9:25 pm